Toutes les études
Inscription sur invitationOBSERVATIONNEL

A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®

This study is gathering information about a medicine called Esperoct® (turoctocog alfa pegol (N8-GP)). It's for males of all ages who have haemophilia A and are already taking Esperoct® to prevent bleeds. The aim is to see how well the medicine works over a long time and if there are any side effects. You'll get the same care you normally would, and your doctor will ask about your health and any bleeds since your last visit. You'll also keep a diary of your bleeds. The study will last about 5 to 7 years. You can choose to leave the study at any time, and it won't affect your medical care.

En un coup d'œil

Statut
Inscription sur invitation
Sponsor
Novo Nordisk A/S
Objectif d'inscription
60
Démarrer
23 Oct 2020
Achèvement estimé
03 Jun 2027

De quoi parle cette étude ?

This study is about a medicine called Esperoct® (sometimes known as turoctocog alfa pegol or N8-GP). It's specifically for males who have haemophilia A. Haemophilia A is a condition where your blood doesn't clot properly, leading to easier bleeding. Esperoct® is a treatment given regularly to help prevent these bleeds.

The main goal of this study is to collect information over a long time – around 5 to 7 years – about how well Esperoct® works in preventing bleeds and whether it causes any side effects. Doctors want to understand its long-term effects in people using it as part of their regular treatment to prevent bleeds.

It's important to know that taking part in this study means you'll continue to get the same medical care and treatment as you usually would. The study is simply looking at how Esperoct® is used in real life. Your participation helps doctors learn more about this medicine to help others with haemophilia A in the future.

Points clés

  • This study is for males with haemophilia A who use Esperoct®.
  • It aims to understand Esperoct®'s long-term effectiveness and side effects.
  • Your treatment and medical care won't change if you join.
  • You'll share information about your bleeds and health over 5-7 years.
  • Participation is voluntary, and you can leave at any time without affecting your care.
  • Your involvement helps improve understanding of haemophilia A treatment.

Qui peut être éligible ?

This study is for males of any age who have been diagnosed with moderate or severe haemophilia A. You must already be using or be about to start using the regular preventive treatment, Esperoct®. The decision for you to use Esperoct® must have been made by you and your doctor independently, before you decide to join this study.

Before you can take part, you'll need to read and sign a consent form, showing you understand what's involved. This is a very important step to make sure you're comfortable with everything.

You cannot join the study if you've been in it before, or if you're allergic to Esperoct® or similar medicines. Also, if your doctor suspects you have 'inhibitors' (antibodies that stop the medicine from working) or if you have difficulty understanding the study information, you won't be able to participate.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Êtes-vous un homme ?
  2. Do you have moderate or severe haemophilia A?
  3. Are you currently using or about to start using Esperoct® for regular prevention?
  4. Has the decision to use Esperoct® already been made by you and your doctor?
  5. Are you comfortable signing a consent form to participate?
  6. Do you understand the study information and feel able to cooperate?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to join this study, it means you'll continue with your usual medical appointments and treatment with Esperoct® as prescribed by your doctor. The study doesn't change your treatment plan. Your clinic visits will be just like your normal check-ups.

During these visits, the study doctor might ask you some questions about your health and if you've had any side effects since your last visit. They might also suggest some routine tests if they think it's helpful. You'll be asked to keep a simple diary at home, noting down any bleeds you have, how you treated them, and when you took your regular Esperoct® medicine.

Your participation in this study will last for quite a while, typically between 5 to 7 years, depending on when you start. You have the right to leave the study at any time, for any reason, and this decision will not affect your current or future medical care in any way.

Risques et avantages potentiels

Taking part in this study won't change your medical care, so you'll continue to receive the same treatment you usually would. There aren't any extra medical procedures for the study, which means no additional medical risks. The main benefit is knowing you're helping medical experts learn more about how Esperoct® works over time, which can help other people with haemophilia A in the future. You always have the right to leave the study at any point, and your care will not be affected.

Locations (27)

  • AKH - Klin. Abt. f. Haematologie u. Haemostaseologie
    Code postal vérifié
    Vienne, Autriche
  • UMHAT "Tsaritsa Yoanna-ISUL"
    Code postal vérifié
    Sofia, Bulgaria
  • KBC Zagreb, Rebro, Hemofilija centar
    Code postal vérifié
    Zagreb, Croatia
  • FN Brno odd. hematologie
    Code postal vérifié
    Brno, Tchéquie
  • FN HK - IV. Interni hematologicka klinika
    Code postal vérifié
    Hradec Králové, Czechia
  • North Estonia Medical Centre Foundation
    Code postal vérifié
    Tallinn, Estonia
  • Tartu University Hospital Haematology Clinic
    Code postal vérifié
    Tartu, Estonia
  • Vivantes Netzwerk für Gesundheit GmbH - Vivantes Klinikum im Friedrichshain
    Code postal vérifié
    Berlin, Allemagne
  • Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie
    Code postal vérifié
    Bonn, Germany
  • "Laiko" General Hospital of Athens
    Code postal vérifié
    Athens, Greece
  • "Laiko" General Hospital of Athens
    Code postal vérifié
    Athens, Greece
  • Aghia Sophia Childrens' Hospital
    Code postal vérifié
    Athens, Greece

Questions fréquentes

What is Esperoct®?

Esperoct® is a medicine used to prevent bleeding in people with haemophilia A.

Do I have to do anything differently with my medicine if I join?

No, you will continue to take Esperoct® exactly as your doctor has prescribed; the study doesn't change your treatment.

Combien de temps l'étude durera-t-elle pour moi ?

The study will last for about 5 to 7 years, depending on when you start.

Can I leave the study whenever I want?

Yes, you are free to leave the study at any time, for any reason, and it won't impact your medical care.

What information will I need to share?

You'll be asked about any bleeds and side effects, and to keep a diary of your bleeds and when you take your medicine.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "A Study Following Males With Haemophilia A on Prophylaxis Wi… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.